EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Activity Profiling of Nitro‐Substituted Di(Hetero)Aryl 1,3,4‐ and 1,2,4‐Oxadiazoles: Antimicrobial, Cholinesterase Inhibition and Antioxidant Potential

Enikő Šikorová iD, Šárka Štěpánková, Eva Frýbová, Klára Konečná, Jana Korbielová, Markéta Švarcová, Ondřej Janďourek, Václav Pflégr iD, Szilvia Bősze, Martin Krátký

Archiv der Pharmazie · 2026

DOI: 10.1002/ardp.70188 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archiv der Pharmazie, 2026. Verfasst von Enikő Šikorová und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czech Republic. Hauptthemen laut MEDLINE: Oxadiazoles, Cholinesterase Inhibitors, Antioxidants, Anti-Bacterial Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agentura Pro Zdravotnický Výzkum České Republiky, Ministerstvo Školství, Mládeže a Tělovýchovy, Charles University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oxadiazole derivatives represent a promising scaffold for drug discovery, offering therapeutic potential, notably against neurodegenerative diseases and microbial infections. Based on molecular hybridisation approach utilising bioactive oxadiazoles, pyridine‐, quinoline‐ and nitrophenyl‐based compounds, we designed novel 1,3,4‐ and 1,2,4‐oxadiazole derivatives containing nitro group(s), evaluated their enzyme inhibition, antimicrobial, and antioxidant properties, and analysed their structure–activity relationships (SAR). Comprehensive activity assessments of them and their synthetic precursors revealed robust inhibitory activity against acetylcholinesterase with IC 50 values as low as 1.47 µM and butyrylcholinesterase (IC 50 ≥ 45.09 μM), outperforming rivastigmine in several cases. Mechanistic insights via molecular docking unveiled unique binding modes for cholinesterases inhibition. Antimicrobial screening demonstrated potent activity (MIC ≥ 2 μM) of several compounds against Mycobacterium tuberculosis , atypical mycobacteria, Gram‐positive bacteria including methicillin‐resistant Staphylococcus aureus , and mould Trichophyton interdigitale . The antioxidant evaluation identified derivatives' free‐radical scavenging potential. SAR analysis identified essential structural features, favouring 3,5‐dinitrophenyl moiety and 1,3,4‐oxadiazoles over 1,2,4‐isomers and 1,2‐diacylhydrazine precursors. In summary, novel candidates for addressing challenges in treating infectious diseases and disorders related to insufficient acetylcholine transmission were identified.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OxadiazolesCholinesterase InhibitorsAntioxidantsAnti-Bacterial AgentsAnti-Infective AgentsStructure-Activity RelationshipMicrobial Sensitivity TestsMolecular Docking SimulationMolecular StructureButyrylcholinesteraseDose-Response Relationship, DrugAcetylcholinesterase

Stichwörter der Autor:innen

antimicrobial activityantioxidant activitycholinesterasesnitro compoundsoxadiazoles

Substanzen

OxadiazolesCholinesterase InhibitorsAntioxidantsAnti-Bacterial AgentsAnti-Infective AgentsButyrylcholinesteraseAcetylcholinesterase

Autor:innen und Institutionen

  • Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czech Republic.
  • Department of Biological and Biochemical Sciences, Faculty of Chemical Technology, University of Pardubice, Pardubice, Czech Republic.
  • Department of Biological and Medical Sciences, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czech Republic.
  • Laboratory for Mycobacterial Diagnostics and Tuberculosis, Regional Institute of Public Health in Ostrava, Ostrava, Czech Republic.
  • HUN-REN-ELTE Research Group of Peptide Chemistry, Hungarian Research Network, Institute of Chemistry, ELTE Eötvös Loránd University, Budapest, Hungary.
  • Department of Genetics, Cell- and Immunobiology, Faculty of Medicine, Semmelweis University, Budapest, Hungary.

ORCID-Profile: Enikő Šikorová, Václav Pflégr

Förderung

  • Agentura Pro Zdravotnický Výzkum České Republiky
  • Ministerstvo Školství, Mládeže a Tělovýchovy
  • Charles University
  • National Research, Development and Innovation Office, Hungary
  • Ministry of Health

Zitieren

APA

Šikorová, E., Štěpánková, Š., Frýbová, E., Konečná, K., Korbielová, J., Švarcová, M., Janďourek, O., Pflégr, V., Bősze, S., & Krátký, M. (2026). Activity Profiling of Nitro‐Substituted Di(Hetero)Aryl 1,3,4‐ and 1,2,4‐Oxadiazoles: Antimicrobial, Cholinesterase Inhibition and Antioxidant Potential. Archiv der Pharmazie. https://doi.org/10.1002/ardp.70188

Vancouver

Šikorová E, Štěpánková Š, Frýbová E, Konečná K, Korbielová J, Švarcová M, et al. Activity Profiling of Nitro‐Substituted Di(Hetero)Aryl 1,3,4‐ and 1,2,4‐Oxadiazoles: Antimicrobial, Cholinesterase Inhibition and Antioxidant Potential. Archiv der Pharmazie. 2026. doi:10.1002/ardp.70188

BibTeX
@article{ikorov2026,
  author = {Šikorová, Enikő and Štěpánková, Šárka and Frýbová, Eva and Konečná, Klára and Korbielová, Jana and Švarcová, Markéta and Janďourek, Ondřej and Pflégr, Václav and Bősze, Szilvia and Krátký, Martin},
  title = {Activity Profiling of Nitro‐Substituted Di(Hetero)Aryl 1,3,4‐ and 1,2,4‐Oxadiazoles: Antimicrobial, Cholinesterase Inhibition and Antioxidant Potential},
  journal = {Archiv der Pharmazie},
  year = {2026},
  doi = {10.1002/ardp.70188}
}
Kostenlos starten →